AstraZeneca stock edges higher as Enhertu approved for metastatic HER2-positive solid tumors

Traders Union
All News
Financial News
AstraZeneca rises 1.15% to GBX14,480 today

Highlights

AstraZeneca's stock gains are driven by EU approval of Enhertu for HER2-positive solid tumors, expanding its oncology franchise.
Additional near-term upside is supported by an EU recommendation for Datroway in metastatic triple-negative breast cancer and early-stage R&D advancements.
Technicals remain bullish, with AZN trading near session highs and strong support at GBX14,125, projected to range between GBX13,707–GBX15,253.

Market optimism rises as EU approvals expand oncology portfolio

The main driver for AstraZeneca's gains is the European Commission's approval of Enhertu, co-developed with Daiichi Sankyo, as a monotherapy for unresectable or metastatic HER2-positive solid tumors in adults previously treated, according to Tradingview and Marketscreener. This regulatory milestone broadens AstraZeneca's market by adding a new indication for Enhertu, fueling expectations of higher adoption and near-term sales potential within oncology. Additional support comes from an EU recommendation for Datroway in first-line treatment for metastatic triple-negative breast cancer in patients ineligible for immunotherapy, as noted by Tradingview, as well as ongoing R&D progress in lung cancer risk detection in Brazil and early-stage acalabrutinib trials in Japan, both highlighted by Tipranks. Collectively, these developments reinforce the company's innovative portfolio and underpin current buying interest.

Mixed technical signals as RSI flags overbought, MACD strong

On the technical front, AZN is trading above the MA-20 at GBX14,163 and MA-50 at GBX13,875 on the hourly chart, as well as above the MA-200 on the daily timeframe at GBX13,670. Immediate support lies at the GBX14,125 Ichimoku Kijun level. Momentum readings present a mixed picture: Moving Average Convergence Divergence (MACD) signals a strong buy, while the Average Directional Index (ADX) is neutral, indicating an uptrend without strong conviction. The Relative Strength Index (RSI) stands at 72.16, highlighting overbought conditions, with the Stochastic RSI and Bull/Bear Power similarly indicating intraday buyer dominance. Commodity Channel Index (CCI) remains in buy territory, while the Awesome Oscillator is neutral, underscoring a moderate divergence between positioning and momentum indicators.

Upside favored as technical and regulatory catalysts converge

In the short term, AZN is expected to trade within a broad range between GBX13,707 and GBX15,253. The probability of further upside is assessed as very high, given the prevailing technical and news-driven backdrop, while the likelihood of a downside move appears low. The primary scenario anticipates consolidation within this band. Upside could accelerate if price breaks above resistance, while a drop below support would likely trigger a short-term correction toward lower levels.

Viktoras Karapetjanc, expert at Traders Union, sees AstraZeneca as primed for further gains. He views the European Commission's approval of Enhertu as a major catalyst, with additional support from new indications and R&D progress. Technicals confirm bullish momentum and reinforce the positive news flow. He believes market sentiment and fundamentals are well aligned. "Strong regulatory wins and innovation keep AstraZeneca on an upward path — I see upside as the dominant scenario now."

Previously it was reported that AstraZeneca sustained its upward momentum, supported by positive regulatory approvals and robust clinical trial updates in the oncology segment. With additional EU endorsements and expanding indications for key therapies now strengthening the fundamental outlook, investors should monitor for a potential breakout above current resistance, which could accelerate near-term upside.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.